Abstract:Introduction: Patients who are considered high-risk for choledocholithiasis after biochemical testing and abdominal ultrasound (AUS) are recommended to undergo endoscopic retrograde cholangiopancreatography (ERCP) with others to receive less invasive tests. The aim of the study is to determine whether high-risk patients by ASGE guidelines or other factors can accurately identify those with choledocholithiasis.Table 1: Diagnostic Performance of ASGE High-Risk Group and Other Test Characteristics in Patients with Suspected Choledocholithiasis ( N =2,726)Methods: Consecutive patients hospitalized (1/2011-12/2013) with suspected choledocholithiasis who received biochemical testing, AUS and definitive testing for choledocholithiasis (magnetic resonance cholangiopancreatography (MRCP), endoscopic ultrasound (EUS), ERCP, interventional radiology procedure and/or intraoperative cholangiogram (IOC)) at Sir Run Run Shaw Hospital were retrospectively identified. Patients with choledocholithiasis on AUS, bilirubin >4mg/dL, bilirubin >1.8mg/dL + dilated common bile duct (CBD) (>8mm and >6mm with or without prior cholecystectomy) and/or suspected cholangitis (presenting fever and/or leukocytosis) were considered high-risk per ASGE guidelines. Final diagnosis was based on choledocholithiasis identified on definitive testing. Results: Mean age of 2,726 patients with suspected choledocholithiasis was 55+15 yrs, 1,179 (43%) were male and 216 (8%) had prior cholecystectomy. On definitive testing (MRCP in 2,441 (90%), EUS in 69 (3%), interventional radiology procedure in 2, ERCP in 643 (23%), IOC in 189 (7%)), 1,076 (39%) patients had choledocholithiasis. A higher proportion of patients meeting ASGE high-risk criteria compared to other groups (770/1,271 (61%) vs. 306/1,455 (21%); OR=5.8, 95%CI 4.9-6.8) had confirmed choledocholithiasis. Diagnostic performance of test characteristics is shown (Table). On multivariate analysis, choledocholithiasis on AUS (AOR=17.4, 95%CI 12.6-23.9), bilirubin >4mg/dL (AOR=3.0, 95%CI 2.2-4.1) and bilirubin 1.8-4mg/dL (AOR=1.8, 95%CI 1.4-2.4) compared to < 1.8mg/dL and CBD dilation (AOR=1.8, 95%CI 1.5-2.2) increased the likelihood of choledocholithiasis. Conclusion: In patients with suspected choledocholithiasis, the specificity of high-risk group categorized by ASGE guidelines was suboptimal. Combination of factors that include choledocholithiasis on AUS and bilirubin >4mg/dL with or without CBD dilation had high specificities of >90% and moderate to high positive likelihood ratios. A revised algorithm with more stringent criteria may improve patient selection and reduce the risk of diagnostic ERCP.

[Diagnostic value of lipoprotein-associated phospholipase A2 in OPBR combined with gallbladder cholesterol deposition].

Strategy for Discriminating Cholesterol and Premalignancy in Polypoid Lesions of the Gallbladder: a Single‐centre, Retrospective Cohort Study

Correlative factors of polypoid lesions of gallbladder in 1095 cases

Evaluation of lipoprotein-associated Phospholipase A2 in Healthy Chinese Han Adult Serum

Suboptimal Specificity of Asge High-Risk Group in Evaluation of Patients with Suspected Choledocholithiasis

Age and incidence of occult pancreaticobiliary reflux in patients with benign gallbladder diseases

Analysis of risk factors for polypoid lesions of gallbladder among health examinees

Association between Lipoprotein-Associated Phospholipase A_2 and Atherothrombosis Stroke

[Clinical Analysis of the Correlation Between Gallbladder Adenomyomatosis and Occult Pancreaticobiliary Reflux].

Correlation between lipoprotein-associated phospholipase A2 and main risk factors in unstable angina pectoris patients

The prognostic value of combined preoperative PLR and CA19-9 in patients with resectable gallbladder cancer

The Correlation Between Lipoprotein-Associated Phospholipase A2 and Severity of Coronary Artery Diseases

Association of lipoprotein lipase (LPL) gene variants with hyperlipidemic acute pancreatitis in southeastern Chinese population

Platelet to lymphocyte ratio as a novel prognostic tool for gallbladder carcinoma.

Clinical Features of Acute Hyperlipidemic Pancreatitis

Association between lipoprotein-associated phospholipase A2 activity and coronary heart disease

The diagnostic value of lipoprotein-associated phospholipase A2 in early diabetic nephropathy

Clinical efficacy of laparoscopic cholecystectomy combined with endoscopic papillary balloon dilation in treatment of gallbladder stones with common bile duct stones: A retrospective study

Study on the correlation between the concentration of plasma lipoprotein-associated phospholipase A2 and coronary heart disease

Lipoprotein-Associated Phospholipase A2 Is a Risk Factor for Patients With Parkinson’s Disease

Synergistic Effect of Lipoprotein-Associated Phospholipase A2 with Classical Risk Factors on Coronary Heart Disease: A Multi-Ethnic Study in China.